- Home
- NRIX vs GDEN Comparison
NRIX vs GDEN Comparison
Compare NRIX & GDEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- GDEN
- Stock Information
- Founded
- NRIX 2009
- GDEN 1998
- Country
- NRIX United States
- GDEN United States
- Employees
- NRIX N/A
- GDEN N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- GDEN Services-Misc. Amusement & Recreation
- Sector
- NRIX Health Care
- GDEN Consumer Discretionary
- Exchange
- NRIX Nasdaq
- GDEN Nasdaq
- Market Cap
- NRIX 750.4M
- GDEN 642.7M
- IPO Year
- NRIX 2020
- GDEN 1999
- Fundamental
- Price
- NRIX $12.78
- GDEN $20.46
- Analyst Decision
- NRIX Strong Buy
- GDEN Buy
- Analyst Count
- NRIX 14
- GDEN 6
- Target Price
- NRIX $26.29
- GDEN $32.33
- AVG Volume (30 Days)
- NRIX 1.7M
- GDEN 220.0K
- Earning Date
- NRIX 10-09-2025
- GDEN 11-06-2025
- Dividend Yield
- NRIX N/A
- GDEN 4.78%
- EPS Growth
- NRIX N/A
- GDEN N/A
- EPS
- NRIX N/A
- GDEN 0.54
- Revenue
- NRIX $83,687,000.00
- GDEN $649,900,000.00
- Revenue This Year
- NRIX $58.48
- GDEN N/A
- Revenue Next Year
- NRIX N/A
- GDEN $2.25
- P/E Ratio
- NRIX N/A
- GDEN $38.71
- Revenue Growth
- NRIX 48.32
- GDEN N/A
- 52 Week Low
- NRIX $8.18
- GDEN $20.87
- 52 Week High
- NRIX $29.56
- GDEN $35.49
- Technical
- Relative Strength Index (RSI)
- NRIX 64.49
- GDEN 30.82
- Support Level
- NRIX $11.37
- GDEN $21.96
- Resistance Level
- NRIX $12.45
- GDEN $22.73
- Average True Range (ATR)
- NRIX 0.75
- GDEN 0.59
- MACD
- NRIX 0.20
- GDEN -0.05
- Stochastic Oscillator
- NRIX 84.06
- GDEN 0.00
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.